119 related articles for article (PubMed ID: 2810909)
1. [Fundamental and clinical evaluation of IRMA for serum pancreatic oncofetal antigen (POA) in pancreatic cancer].
Honjo K; Hirano F; Sakai N; Uehara S; Hirayama A; Nakamura T; Ihara K; Tanaka H
Kaku Igaku; 1989 Jul; 26(7):907-14. PubMed ID: 2810909
[No Abstract] [Full Text] [Related]
2. [Fundamental and clinical evaluation of IRMA for serum pancreatic oncofetal antigen (POA)].
Murakami M; Fukuchi M
Kaku Igaku; 1988 Feb; 25(2):161-9. PubMed ID: 3164428
[No Abstract] [Full Text] [Related]
3. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
[No Abstract] [Full Text] [Related]
4. [Fundamental studies of a pancreatic oncofetal antigen immunoradiometric assay kit].
Nagata A; Komoda T
Kaku Igaku; 1988 Dec; 25(12):1445-55. PubMed ID: 3249464
[No Abstract] [Full Text] [Related]
5. [Fundamental and clinical evaluation of IRMA for serum SPan-1 antigen].
Fukuda Y; Murakami M; Fukuchi M
Kaku Igaku; 1990 Apr; 27(4):405-13. PubMed ID: 2165543
[No Abstract] [Full Text] [Related]
6. [Evaluation of a cytokeratin 19 assay kit "BALL ELSA CYFRA21-1"].
Sakahara H; Kousaka T; Hattori N; Hosono M; Kobayashi H; Shirato M; Yao Z; Konishi J
Kaku Igaku; 1993 Dec; 30(12):1475-9. PubMed ID: 7509008
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
Nishida K
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
[TBL] [Abstract][Full Text] [Related]
8. [A basic and clinical evaluation of a new immunoradiometric assay kit for human serum tissue polypeptide antigen (TPA)].
Shimojo K; Watanabe N; Sakai S; Kobayashi M; Ohtake H; Hatori N; Fukasawa K; Tomiyoshi K; Inoue T; Endo K
Kaku Igaku; 1996 Jun; 33(6):655-61. PubMed ID: 8741511
[TBL] [Abstract][Full Text] [Related]
9. [Basic and clinical studies on SPan-1 RIABEAD kit: usefulness in patients with pancreatic and biliary tract cancer].
Watanabe Y; Endo K; Nakajima K; Hattori N; Sakahara H; Saga T; Nakai T; Hosono M; Yao ZS; Baba N
Kaku Igaku; 1989 Dec; 26(12):1559-65. PubMed ID: 2622087
[No Abstract] [Full Text] [Related]
10. [Basic and clinical studies of serum CA195 antigen assay with "BL-CA195" kit].
Kobayashi M; Yamaguchi A; Imai T; Otake H; Igarashi H; Hatori N; Tomiyoshi K; Inoue T; Endo K; Sakahara H
Kaku Igaku; 1993 Apr; 30(4):441-7. PubMed ID: 8315895
[TBL] [Abstract][Full Text] [Related]
11. [Basic study of CA125 measurement using a newly developed "SD-8729" IRMA kit].
Yamaguchi A; Kobayashi M; Imai T; Otake H; Matsubara K; Hatori N; Tomiyoshi K; Inoue T; Endo K
Kaku Igaku; 1993 Oct; 30(10):1245-52. PubMed ID: 8264116
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease.
Cooper EH; Forbes MA; Taylor M
Br J Cancer; 1990 Dec; 62(6):1004-5. PubMed ID: 2257202
[No Abstract] [Full Text] [Related]
13. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients.
Silén A; Wiklund B; Andersson EL; Nilsson S
Scand J Clin Lab Invest; 1995 Apr; 55(2):153-61. PubMed ID: 7545308
[TBL] [Abstract][Full Text] [Related]
14. [Pancreatic oncofetal antigen (POA) and carcinoma of the pancreas].
Homma T; Oguchi H; Kawa S; Nagata A; Furuta S
Gan No Rinsho; 1984 May; 30(6 Suppl):558-62. PubMed ID: 6205174
[TBL] [Abstract][Full Text] [Related]
15. [Pancreatic oncofetal antigen (POA)].
Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002
[TBL] [Abstract][Full Text] [Related]
16. [The evaluation of the newly produced assay kit for the cytokeratin fragment, "ball ELSA CYFRA21-1"].
Kimura Y; Ata M; Nakamura S; Fujii T; Kawamura T; Tanada S; Hamamoto K
Kaku Igaku; 1994 Feb; 31(2):199-206. PubMed ID: 7509886
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of contrast agents during immunoradiometric assay for tumour-associated antigens.
Watanabe N; Oriuchi N; Higuchi T; Yukihiro M; Fukushima Y; Tomiyoshi K; Hirano T; Inoue T; Endo K
Nucl Med Commun; 1998 Jan; 19(1):63-70. PubMed ID: 9515548
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas.
Shahangian S; Fritsche HA; Hughes JI; Gelder FB
Clin Chem; 1989 Mar; 35(3):405-8. PubMed ID: 2537687
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mice.
Li L; Yue GG; Fung KP; Leung PC; Lau CB; Leung PS
Pancreas; 2014 Oct; 43(7):1126-8. PubMed ID: 25207664
[No Abstract] [Full Text] [Related]
20. Developments in serologic detection of human pancreatic adenocarcinoma.
Eskelinen M; Haglund U
Scand J Gastroenterol; 1999 Sep; 34(9):833-44. PubMed ID: 10522599
[No Abstract] [Full Text] [Related]
[Next] [New Search]
